论文部分内容阅读
为了动态观察急性髓系白血病（AML）完全缓解（CR）前后的克隆性演变及其与骨髓细胞染色体核型和临床转归的关系。采用人雄激素受体（HUMARA）基因多态性──甲基化分析的方法对15例杂合子女性AML患者缓解前后的克隆性进行了分析。结果显示：15例AML患者缓解方均为单克隆造血，经化疗完全缓解（CR）后其中的11的恢复为多克隆性造血，余4例仍为单克隆性造血，后者中的一例在检查后3个月复发，未发现CR后的克隆性与骨髓三系病态造血有何关系。AML为一克隆性疾病，大部分AML患者CR后恢复正常多克隆性造血，但的有1／4的患者仍为单克隆造血。
To observe the clonal evolution before and after complete remission (CR) of acute myeloid leukemia (AML) and its relationship with karyotype and clinical outcome of bone marrow cells. The human androgenetic hormone receptor (HUMARA) gene polymorphism-methylation analysis was used to analyze the clonality of 15 heterozygous female AML patients before and after remission. The results showed that: 15 cases of AML patients were all monoclonal hematopoietic remission, after chemotherapy complete remission (CR) 11 of the recovery of polyclonal hematopoiesis, the remaining 4 cases of monoclonal hematopoietic, one of the latter in Three months after the examination, there was no recurrence. No correlation was found between clonality after CR and pathological hematopoiesis in the triple line of bone marrow. AML is a clonal disease. Most AML patients recover normal polyclonal hematopoiesis after CR, but 1/4 of patients still have monoclonal hematopoiesis.